ADVERTISEMENT
Piramal Pharma Q2 Results Review - Operating Performance Above Estimate; FY25 Guidance Intact: Motilal Oswal
With enhanced inquiries on the CDMO front at industry level in India, the brokerage believes the company is well poised to benefit from its differentiated capabilities and capacities.
25 Oct 2024, 02:35 PM IST 
Colorful pills. (Source: freepik)
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
